A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).

Hongyun Zhao; Zhonghan Zhang; Fan Luo; Yuxiang Ma; Wenfeng Fang; Yunpeng Yang; Yang Zhang; Yan Huang; Li Zhang

doi:10.1200/jco.2018.36.15_suppl.tps9116

A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps9116 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS9116-TPS9116

Author(s):

Hongyun Zhao ◽

Zhonghan Zhang ◽

Fan Luo ◽

Yuxiang Ma ◽

Wenfeng Fang ◽

...

Keyword(s):

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

118TiP A multicenter, randomized, double-blind, placebo-controlled phase III trial of camrelizumab plus chemotherapy with or without radiation therapy (RT) as first-line treatment for patients with brain metastatic non-small cell lung cancer (BM-NSCLC; CTONG2003): Trial in progress

Annals of Oncology ◽

10.1016/j.annonc.2021.10.136 ◽

2021 ◽

Vol 32 ◽

pp. S1426-S1427

Author(s):

J. Yang ◽

Y. Pan ◽

F. Ning ◽

L. Lin ◽

X. Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

First Line Treatment

Download Full-text

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283381.78585.f2 ◽

2007 ◽

Vol 2 (8) ◽

pp. S451

Author(s):

Eng-Huat Tan ◽

Tomasz Grodzki ◽

Claus-Peter Schneider ◽

Peter Zatloukal ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Squire: a Randomized, Multicenter, Open-Label, Phase III Study of Gemcitabine-Cisplatin (Gc) Chemotherapy Plus Necitumumab (Imc-11F8/Ly3012211) Vs Gc Alone in the First-Line Treatment of Patients (Pts) with Stage Iv Squamous Non-Small Cell Lung Cancer (Sq-Nsclc): Update on Key Subgroups

Annals of Oncology ◽

10.1093/annonc/mdu349.11 ◽

2014 ◽

Vol 25 ◽

pp. iv430 ◽

Cited By ~ 1

Author(s):

M.A. Socinski ◽

L. Paz-Ares ◽

A.V. Luft ◽

A. Szczesna ◽

T.E. Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3-3 ◽

Cited By ~ 70

Author(s):

R. Pirker ◽

A. Szczesna ◽

J. von Pawel ◽

M. Krzakowski ◽

R. Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8008 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8008-8008 ◽

Cited By ~ 18

Author(s):

Nick Thatcher ◽

Fred R. Hirsch ◽

Aleksandra Szczesna ◽

Tudor-Eliade Ciuleanu ◽

Wojciech Szafranski ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A multi-center, randomized, double-blind, parallel, two-group phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdy442 ◽

2018 ◽

Vol 29 ◽

pp. ix121 ◽

Cited By ~ 1

Author(s):

B. Han ◽

K. Li ◽

T. Chu ◽

M. Bi ◽

H. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of Onartuzumab (METMAB) with Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum as First-Line Treatment for Patients (PTS) with Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Annals of Oncology ◽

10.1016/s0923-7534(20)33827-8 ◽

2012 ◽

Vol 23 ◽

pp. ix445

Author(s):

H. Wakelee ◽

W. Yu ◽

K. Rittweger ◽

V.E. Paton

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Controlled Study ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdz063.070 ◽

2019 ◽

Vol 30 ◽

pp. ii62

Author(s):

B. Han ◽

K. Li ◽

T. Chu ◽

M. Bi ◽

H. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Study ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

First Line Treatment

Download Full-text

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdn774 ◽

2009 ◽

Vol 20 (7) ◽

pp. 1249-1256 ◽

Cited By ~ 43

Author(s):

E.H. Tan ◽

J. Rolski ◽

T. Grodzki ◽

C.P. Schneider ◽

U. Gatzemeier ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text